The FDA has granted Fast Track Designation to Sanofi’s SAR402663, an investigational one-time intravitreal gene therapy for ...

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degenerationDesignation earned for a one-time ...

A gene therapy for neovascular age-related macular degeneration in the second eye shows safety and preservation of vision and ...

Sanofi said its gene therapy to treat neovascular age-related macular degeneration was approved for fast-track development in the U.S. The biopharmaceutical company said Thursday that the Food and ...

Sanofi SNY announced that the FDA granted fast track designation to its investigational gene therapy, SAR402663, for the ...

An international group of retina specialists recently reached consensus on a two-step process for the identification of ...

SAR402663 is an investigational one-time intravitreal gene therapy that delivers genetic material encoding soluble FLT01.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, ...

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1Over 60% of people with a ...

Please provide your email address to receive an email when new articles are posted on . Neovascular glaucoma (NVG) is historically known as rubeotic glaucoma, from the rubeosis iridis that refers to ...

Neovascular age-related macular degeneration is responsible for the overwhelming majority of vision loss in age-related macular degeneration. Not too long ago, the disease was poorly controlled with ...